创伤性颅脑损伤合并颅内出血患者中创伤性脑静脉窦损伤的管理与结局
抗血小板治疗(32%)和抗凝治疗(19%)均与更好的预后相关,抗血小板治疗独立关联更低的30天死亡率,随访再通状态与临床结局不相关。
要点
- tCVSI在筛查人群中占2.2%,抗凝治疗出血并发症为31%,抗血小板治疗为10%。
- 抗血小板(OR 6.5)和抗凝(OR 4.7)治疗均与更好预后相关。
- 抗血小板治疗独立关联更低的30天死亡率(OR 0.2)。
核心结论
- 抗血小板和抗凝治疗均与tCVSI患者良好预后相关,抗血小板治疗独立关联更低的30天死亡率。
- 随访再通状态与临床结局不相关,提示tCVSI需不同于自发性CVST的治疗策略。
研究设计与样本
- 回顾性多中心研究,纳入2018至2024年3家一级创伤中心影像学确诊的tCVSI患者。
主要发现
- 抗血小板治疗用于32%患者,抗凝治疗用于19%患者。
- 抗凝治疗患者出血并发症发生率为31%,抗血小板治疗患者为10%。
- 73.9%患者获得良好结局(扩展格拉斯哥结局量表评分≥5),30天死亡率为12.6%。
- 多因素分析显示抗血小板治疗(OR 6.5,95%CI 2.1-20.0)和抗凝治疗(OR 4.7,95%CI 1.3-17.7)均与更好结局相关。
- 抗血小板治疗独立关联更低的30天死亡率(OR 0.2,95%CI 0.06-0.66)。
关键数值与推荐
- 随访时39.9%患者受累静脉窦完全再通,17.5%部分再通,42.7%无变化。
- 重复影像的再通状态与临床结局不相关。
临床怎么用
- 对于tCVSI患者,抗血小板或抗凝治疗可能与更好预后相关,抗血小板治疗或可降低30天死亡率。
- 随访影像的再通状态不宜作为临床结局的替代指标。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Traumatic cerebral venous sinus injury (tCVSI) is a rare but serious complication of traumatic brain injury. Although similar radiographically to spontaneous cerebral venous sinus thrombosis (CVST), tCVSI treatment approaches have not been fully investigated. We characterized complications, clinical outcomes, and recanalization in tCVSI and evaluated treatment approaches. METHODS: In this retrospective review of patients with radiographically confirmed tCVSI across 3 Level 1 trauma centers from 2018 to 2024, we collected patient characteristics, injury patterns, treatment modalities, complications, clinical outcomes, and recanalization data. Primary outcomes were favorable recovery (extended Glasgow Outcome Scale score ≥5) and 30-day mortality. Multivariate regression identified independent predictors of outcomes and recanalization. RESULTS: Among 11 300 patients screened, 254 (2.2%) had tCVSI. Antiplatelet (AP) and anticoagulation (AC) therapy were used in 32% and 19% of patients, respectively. Hemorrhagic complications occurred in 31% of patients treated with AC and 10% receiving AP. Favorable outcomes were achieved in 73.9% of patients, and 30-day mortality was 12.6%. On multivariate analysis, AP (odds ratio [OR] 6.5, 95% CI 2.1-20.0) and AC (OR 4.7, 95% CI 1.3-17.7) therapies were both associated with better outcomes. AP therapy was independently associated with lower 30-day mortality (OR 0.2, 95% CI 0.06-0.66). At the follow-up, 39.9% of patients had complete recanalization of the involved sinus, 17.5% had partial recanalization, and 42.7% were unchanged. Recanalization status on repeat imaging did not correlate with clinical outcomes. CONCLUSION: This multicenter series demonstrates treatment response in patients after tCVSI and describes differences in natural history compared with spontaneous CVST. Both antithrombotic regimens were associated with favorable outcomes, and AP therapy was independently associated with lower mortality, suggesting a potential role in tCVSI management. Recanalization status at follow-up appeared unrelated to clinical outcomes, supporting the need for unique therapeutic approaches for tCVSI compared with spontaneous CVST, particularly in the acute management period.
引用
- Brown J, Hamrick F, Abo Kasem R, et al. Management and Outcomes of Traumatic Cerebral Venous Sinus Injury Among Patients With Traumatic Brain Injury and Concomitant Intracranial Hemorrhage. Neurosurgery. 2026. PMID: 41960924. doi:10.1227/neu.0000000000004027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。